Medical Oncology

, Volume 26, Issue 2, pp 117–123 | Cite as

Prediction of prognosis in gallbladder carcinoma by CD147 and MMP-2 immunohistochemistry

  • Wei Wu
  • Rongbing Wang
  • Hui Liu
  • Jie Peng
  • Damao Huang
  • Bo Li
  • Jingde Ruan
Original Paper
First Online:
Received:
Accepted:

Abstract

Aim To investigate whether the presence of CD147 and MMP-2 in cancerous gallbladder tissues might help us to predict the patients’ prognosis. Methods Tissue samples from 168 patients with gallbladder carcinomas and 37 patients with chronic cholecystitis were stained with anti-CD147 and anti-MMP-2 antibodies for immunohistochemical analysis. Then, the association of their expression with clinicopathologic characteristics and 108 patients’ prognosis was analyzed. Results CD147 and MMP-2 were detected mainly in cancerous tissues, but also expressed in some chronic cholecystitis patients. Out of 168 patients with gallbladder carcinoma 121 (72.02%) and 136 (80.95%) patients showed CD147 and MMP-2 positive expression, whereas the 37 patients with chronic cholecystitis only 5 (13.51%) and 3 (8.11%) patients expressed them, respectively. Pathologic findings demonstrated that the intensity of CD147 and MMP-2 staining in cancerous tissues was associated significantly with histological types (P = 0.03), distant metastasis (P < 0.01), and Nevin stages (P = 0.02) of gallbladder carcinomas. Using a proportional hazard model, the survival rate of the patients with CD147+/MMP-2+ expression was the lowest (P < 0.01), and including information on CD147 and MMP-2 staining patterns within cancerous tissues along with clinical cancer staging may improve the accuracy of predicting patients’ prognosis. Conclusion The results suggest that the expression of CD147 and MMP-2 may be an important feature of gallbladder carcinomas. The detection of these two markers combined with cancerous staging may increase the ability of investigators to predict the prognosis of patients with gallbladder carcinomas.

Keywords

Gallbladder carcinoma CD147 MMP-2 Immunohistochemistry Clinicopathology Prognosis 

Abbreviations

CD147

Extracellular matrix metalloproteinase inducer

MMP

Matrix metalloproteinases

ECM

Extracellular matrix

This is a preview of subscription content, log in to check access.

References

  1. 1.
    Pulukuri S, Patel J, Estes N, Rao JS. Matrix metalloproteinase-1 (MMP-1) expression and biological significance in the progression of prostate cancer. American Association for Cancer Research Annual Meeting, 2007. p. 14–18.Google Scholar
  2. 2.
    Nabeshima K, Suzumiya J, Nagano M, et al. Emmprin, a cell surface inducer of matrix metalloproteinases, is expressed in T-cell lymphomas. J Pathol. 2004;202:341–51. doi: 10.1002/path.1518.PubMedCrossRefGoogle Scholar
  3. 3.
    Sidhu SS, Mengistab AT, Tauscher AN, et al. The microvesicle as a vehicle for EMMPRIN in tumorstromal interactions. Oncogene. 2004;23:956–63. doi: 10.1038/sj.onc.1207070.PubMedCrossRefGoogle Scholar
  4. 4.
    Millimaggi D, Mari M, D’Ascenzo S, et al. Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia. 2007;9:349–57. doi: 10.1593/neo.07133.PubMedCrossRefGoogle Scholar
  5. 5.
    Ben D, Iris G, Aasmund B. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis. 2003;20:161–9. doi: 10.1023/A:1022696012668.CrossRefGoogle Scholar
  6. 6.
    Tsai W-C, Chao Y-C, Sheu L-F, et al. EMMPRIN and fascin overexpression associated with clinicopathologic parameters of pancreatobiliary adenocarcinoma in Chinese people. APMIS. 2007;115:929–38.PubMedCrossRefGoogle Scholar
  7. 7.
    Anxin S, Martin EH. Regulation of MMP-1 and MMP-2production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res. 2001;61:2276–81.Google Scholar
  8. 8.
    Stanley Z, Michelle H, Ellen E, et al. Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol. 2001;158:1921–8.Google Scholar
  9. 9.
    Yi T, Prabakaran K, Marian T. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Molecular Cancer Res. 2004;2:73–80.Google Scholar
  10. 10.
    Mi Z, Oliver T, Guo H, et al. Thrombin-cleaved COOH (−) terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells. Cancer Res. 2007;67:4088–97. doi: 10.1158/0008-5472.CAN-06-4066.PubMedCrossRefGoogle Scholar
  11. 11.
    Sabine R, Natalie R, Volker A, et al. High incidence of EMMPRIN expression in human tumors. Int J Cancer. 2006;119:1800–10. doi: 10.1002/ijc.22062.CrossRefGoogle Scholar
  12. 12.
    Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating ascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 2005;65:3193–9.CrossRefGoogle Scholar
  13. 13.
    Gabison EE, Mourah S, Steinfels E, et al. Diverential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas: role in epithelio- stromal interactions and matrix metalloproteinase induction. Am J Pathol. 2005;166:209–19.PubMedGoogle Scholar
  14. 14.
    Nabeshima K, Iwasaki H, Koga K, et al. Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int. 2006;56:359–67. doi: 10.1111/j.1440-1827.2006.01972.x.PubMedCrossRefGoogle Scholar
  15. 15.
    Erica AM, Alexandra Z-J, Rongsong L. Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res. 2004;64:1229–32. doi: 10.1158/0008-5472.CAN-03-2832.CrossRefGoogle Scholar
  16. 16.
    HaiGang L, DeRong X, XiMing S. Clinicopathological significance of expression of paxillin, syndecan-land EMMPRIN in hepatocellular carcinoma. World J Gastroenterol. 2005;11:1445–51.Google Scholar
  17. 17.
    Cheng MF, Tzao C, Tsai W-C, et al. Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters. Dis Esophagus. 2006;19:482–6. doi: 10.1111/j.1442-2050.2006.00613.x.PubMedCrossRefGoogle Scholar
  18. 18.
    Lee JW, Song SY, Choi JJ, et al. Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Hum Pathol. 2005;36:626–33. doi: 10.1016/j.humpath.2005.03.003.PubMedCrossRefGoogle Scholar
  19. 19.
    Tsai W-C, Sheu L-F, Nieh S, et al. Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters. World J Urol. 2007;25:73–80. doi: 10.1007/s00345-006-0110-2.PubMedCrossRefGoogle Scholar
  20. 20.
    Tang Y, Nakada MT, Kesavan P, et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 2005;65:3193–9.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2008

Authors and Affiliations

  • Wei Wu
    • 1
  • Rongbing Wang
    • 2
  • Hui Liu
    • 3
  • Jie Peng
    • 4
  • Damao Huang
    • 5
  • Bo Li
    • 6
  • Jingde Ruan
    • 1
  1. 1.Department of Geriatric SurgeryXiangya Hospital, Central South UniversityChangshaPeople’s Republic of China
  2. 2.National Hepatobiliary & Enteric Surgery Research CenterChangshaPeople’s Republic of China
  3. 3.The 3rd Department of Hepatic SurgeryEastern Hepatobiliary Surgery Hospital, Second Military Medical UniversityShanghaiPeople’s Republic of China
  4. 4.Department of GastroenterologyXiangya Hospital, Central South UniversityChangshaPeople’s Republic of China
  5. 5.Department of Clinical LaboratoryXiangya Hospital, Central South UniversityChangshaPeople’s Republic of China
  6. 6.Department of PathologyXiangya Hospital, Central South UniversityChangshaPeople’s Republic of China

Personalised recommendations